US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Certara, Inc. - Common Stock (NQ:CERT)

9.360 +0.020 (+0.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Decoding 4 Analyst Evaluations For Certara ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 4 Ratings For Certara ↗
 
Via Benzinga
News headline image
Certara Reports Fourth Quarter 2023 Financial Results
Provides Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Recap: Certara Q3 Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Certara ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Certara ↗
 
Via Benzinga
News headline image
Looking Into Certara's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Tax Season Is Here: Meet The New Federal Program That Can Eat Away At Tax Preparation Companies ↗
New IRS program launching for free tax filing could affect tax prep companies like H&R Block and Intuit. Market share drop could impact ETFs. 
Via Benzinga
News headline image
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development. 
From Certara
Via GlobeNewswire
News headline image
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies 
From Certara
Via GlobeNewswire
News headline image
Analyst Expectations for Certara's Future ↗
 
Via Benzinga
News headline image
Certara Reports Third Quarter 2023 Financial Results
Reiterates Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
News headline image
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations 
From Certara
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Certara Reports Second Quarter 2023 Financial Results
Provides Update to Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Certara Reports First Quarter 2023 Financial Results
Reiterates 2023 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
Asserts Certara’s leadership in advancing the development and approval of new drugs for patients 
From Certara
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023 ↗
 
Via Benzinga
News headline image
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >